Epithelial ovarian cancer Trials in San Antonio, United States
Conditions / Epithelial ovarian cancer / San Antonio, United States
Epithelial ovarian cancer is a medical condition with active clinical research programs worldwide.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06890338 | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | RECRUITING | — |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression | COMPLETED | PHASE3 |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | TERMINATED | PHASE2/PHASE3 |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | RECRUITING | PHASE3 |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | RECRUITING | PHASE1 |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | COMPLETED | PHASE1 |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |